| [1] Owen M, Friedenstein AJ. Stromal stem cells: marrow- derived osteogenic precursors. Ciba Found Symp, 1988, 136(1): 42–60.<\p>
[2] Caplan A, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med, 2001, 7(6): 259–264.<\p>
[3] Chen Y, Shao JZ, Xiang LX, Dong XJ, Zhang GR. Mes-enchymal stem cells: a promising candidate in regenera-tive medicine. Int J Biochem Cell Biol, 2008, 40(5): 815– 820.<\p>
[4] Caplan AI. Mesenchymal stem cells. J Orthop Res, 1991, 9(5): 641–650.<\p>
[5] Baksh D, Boland GM, Tuan RS. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differen-tiation. J Cell Biochem, 2007, 101(5): 1109–1124.<\p>
[6] McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell, 2004, 6(4): 483–495.<\p>
[7] Wu R, Liu G, Bharadwaj S, Zhang Y. Isolation and myogenic differentiation of mesenchymal stem cells for urologic tis- sue engineering. Methods Mol Biol, 2013, 1001(1): 65–80.<\p>
[8] Beier JP, Bitto FF, Lange C, Klumpp D, Arkudas A, Ble-iziffer O, Boos AM, Horch RE, Kneser U. Myogenic dif-ferentiation of mesenchymal stem cells co-cultured with primary myoblasts. Cell Biol Int, 2011, 35(4): 397– 406.<\p>
[9] Lee KD. Applications of mesenchymal stem cells: an up-dated review. Chang Gung Med J, 2008, 31(3): 228–236.<\p>
[10] Ramos A and Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol, 2012, 22(7): 339– 346.<\p>
[11] Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol, 2011, 13(8): 877–883.<\p>
[12] Byun MR, Jeong H, Bae SJ, Kim AR, Hwang ES, Hong JH. TAZ is required for the osteogenic and anti-adipogenic ac-tivities of kaempferol. Bone, 2012, 50(1): 364–372.<\p>
[13] Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Sci-ence, 2005, 309(5737): 1074–1078.<\p>
[14] Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol, 2008, 20(6): 638–646.<\p>
[15] Mao YP, Mulvaney J, Zakaria S, Yu T, Morgan KM, Allen S, Basson MA, Francis-West P, Irvine KD. Characteriza-tion of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development, 2011, 138(5): 947–957.<\p>
[16] Zhao B, Li L, Lei QY, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis. Genes Dev, 2010, 24(9): 862–874.<\p>
[17] 许传铭, 万福生. 哺乳动物Hippo信号通路: 肿瘤治疗的新标靶. 遗传, 2012, 34(3): 269–280.<\p>
[18] Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB. TAZ: a novel transcriptional co-activator regu-lated by interactions with 14-3-3 and PDZ domain proteins. EMBO J, 2000, 19(24): 6778–6791.<\p>
[19] Zhao B, Wei XM, Li WQ, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu JD, Li L, Zheng P, Ye KQ, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP onco-protein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev, 2007, 21(21): 2747–2761.<\p>
[20] Hong WJ, Guan KL. The YAP and TAZ transcription co-activators: Key downstream effectors of the mammal-ian Hippo pathway. Seminars Cell Dev Biol, 2012, 23(7): 785–793.<\p>
[21] Bork P, Sudol M. The WW domain: a signalling sit |
